Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-06 · accession 0000950170-25-036711 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-10 | 2025-03-06 | AMLX | Klee Justin B. | Co-CEO, Dir | A - Grant | $0.00 | +180.1K | 3.38M | +6% | $0 |
| D | 2025-03-10 | 2025-03-06 | AMLX | Klee Justin B. | Co-CEO, Dir | A - Grant | $0.00 | +270.2K | 270.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-06 | A | A | 180,118 | $0.00 | 3,376,766 | D | — | — | (F1) The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-03-06 | A | A | 270,177 | $0.00 | 270,177 | D | $3.61 · — to 2035-03-05 | 270,177 Common Stock | (F2) 25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |